T Bachelot1, E Ciruelos2, A Schneeweiss3, F Puglisi4, T Peretz-Yablonski5, I Bondarenko6, S Paluch-Shimon7, A Wardley8, J-L Merot9, Y du Toit10, V Easton10, N Lindegger10, D Miles11. 1. Medical Oncology Department, Centre Léon Bérard, Lyon, France. Electronic address: thomas.bachelot@lyon.unicancer.fr. 2. Medical Oncology Department Breast Care Unit, Hospital Universitario 12 de Octubre, Madrid, Spain. 3. Gynecologic Oncology Division, National Center for Tumor Diseases, University Hospital and German Cancer Research Center, Heidelberg, Germany. 4. IRCCS Centro di Riferimento Oncologico Aviano-National Cancer Institute, Aviano; Department of Medicine, University of Udine, Udine, Italy. 5. Sharett Institute of Oncology and Center for Malignant Breast Diseases, Hadassah Medical Organization, Jerusalem, Israel. 6. City Clinical Hospital No. 4, Dnipropetrovsk, Ukraine. 7. Breast Oncology Unit, Shaare Zedek Medical Centre, Jerusalem, Israel. 8. The NIHR Manchester Clinical Research Facility at the Christie NHS Foundation Trust, Manchester; Faculty of Biology Medicine & Health, Division of Cancer Sciences, School of Medical Sciences, University of Manchester, Manchester, UK. 9. Medical and Scientific Services, Oncology Therapeutic Unit, IQVIA, Saint Ouen, France. 10. Global Product Development Medical Affairs Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland. 11. Mount Vernon Cancer Centre, Middlesex, UK.
Abstract
BACKGROUND: Pertuzumab combined with trastuzumab and docetaxel is the standard first-line therapy for HER2-positive metastatic breast cancer, based on results from the phase III CLEOPATRA trial. PERUSE was designed to assess the safety and efficacy of investigator-selected taxane with pertuzumab and trastuzumab in this setting. PATIENTS AND METHODS: In the ongoing multicentre single-arm phase IIIb PERUSE study, patients with inoperable HER2-positive advanced breast cancer (locally recurrent/metastatic) (LR/MBC) and no prior systemic therapy for LR/MBC (except endocrine therapy) received docetaxel, paclitaxel or nab-paclitaxel with trastuzumab [8 mg/kg loading dose, then 6 mg/kg every 3 weeks (q3w)] and pertuzumab (840 mg loading dose, then 420 mg q3w) until disease progression or unacceptable toxicity. The primary end point was safety. Secondary end points included overall response rate (ORR) and progression-free survival (PFS). RESULTS: Overall, 1436 patients received at least one treatment dose (initially docetaxel in 775 patients, paclitaxel in 589, nab-paclitaxel in 65; 7 discontinued before starting taxane). Median age was 54 years; 29% had received prior trastuzumab. Median treatment duration was 16 months for pertuzumab and trastuzumab and 4 months for taxane. Compared with docetaxel-containing therapy, paclitaxel-containing therapy was associated with more neuropathy (all-grade peripheral neuropathy 31% versus 16%) but less febrile neutropenia (1% versus 11%) and mucositis (14% versus 25%). At this preliminary analysis (52 months' median follow-up), median PFS was 20.6 [95% confidence interval (CI) 18.9-22.7] months overall (19.6, 23.0 and 18.1 months with docetaxel, paclitaxel and nab-paclitaxel, respectively). ORR was 80% (95% CI 78%-82%) overall (docetaxel 79%, paclitaxel 83%, nab-paclitaxel 77%). CONCLUSIONS: Preliminary findings from PERUSE suggest that the safety and efficacy of first-line pertuzumab, trastuzumab and taxane for HER2-positive LR/MBC are consistent with results from CLEOPATRA. Paclitaxel appears to be a valid alternative taxane backbone to docetaxel, offering similar PFS and ORR with a predictable safety profile. CLINICALTRIALS.GOV: NCT01572038.
BACKGROUND:Pertuzumab combined with trastuzumab and docetaxel is the standard first-line therapy for HER2-positive metastatic breast cancer, based on results from the phase III CLEOPATRA trial. PERUSE was designed to assess the safety and efficacy of investigator-selected taxane with pertuzumab and trastuzumab in this setting. PATIENTS AND METHODS: In the ongoing multicentre single-arm phase IIIb PERUSE study, patients with inoperable HER2-positive advanced breast cancer (locally recurrent/metastatic) (LR/MBC) and no prior systemic therapy for LR/MBC (except endocrine therapy) received docetaxel, paclitaxel or nab-paclitaxel with trastuzumab [8 mg/kg loading dose, then 6 mg/kg every 3 weeks (q3w)] and pertuzumab (840 mg loading dose, then 420 mg q3w) until disease progression or unacceptable toxicity. The primary end point was safety. Secondary end points included overall response rate (ORR) and progression-free survival (PFS). RESULTS: Overall, 1436 patients received at least one treatment dose (initially docetaxel in 775 patients, paclitaxel in 589, nab-paclitaxel in 65; 7 discontinued before starting taxane). Median age was 54 years; 29% had received prior trastuzumab. Median treatment duration was 16 months for pertuzumab and trastuzumab and 4 months for taxane. Compared with docetaxel-containing therapy, paclitaxel-containing therapy was associated with more neuropathy (all-grade peripheral neuropathy 31% versus 16%) but less febrile neutropenia (1% versus 11%) and mucositis (14% versus 25%). At this preliminary analysis (52 months' median follow-up), median PFS was 20.6 [95% confidence interval (CI) 18.9-22.7] months overall (19.6, 23.0 and 18.1 months with docetaxel, paclitaxel and nab-paclitaxel, respectively). ORR was 80% (95% CI 78%-82%) overall (docetaxel 79%, paclitaxel 83%, nab-paclitaxel 77%). CONCLUSIONS: Preliminary findings from PERUSE suggest that the safety and efficacy of first-line pertuzumab, trastuzumab and taxane for HER2-positive LR/MBC are consistent with results from CLEOPATRA. Paclitaxel appears to be a valid alternative taxane backbone to docetaxel, offering similar PFS and ORR with a predictable safety profile. CLINICALTRIALS.GOV: NCT01572038.
Authors: Maria Mitsogianni; Ioannis P Trontzas; Georgia Gomatou; Stephanie Ioannou; Nikolaos K Syrigos; Elias A Kotteas Journal: Oncol Lett Date: 2021-02-12 Impact factor: 2.967
Authors: Marc Thill; Pauline Wimberger; Andrea Grafe; Peter Klare; Kerstin Luedtke-Heckenkamp; Dietmar Reichert; Matthias Zaiss; Katja Ziegler-Löhr; Tanja Eckl; Andreas Schneeweiss Journal: Breast Cancer Res Treat Date: 2022-09-12 Impact factor: 4.624
Authors: Kausar Suleman; Ali Hassan Mushtaq; Emaan Haque; Ahmed Ali Badran; Dahish Ajarim; Ahmed Mohammed Elashwah; Ahmed Mostafa Gad; Amgad Shaheen Abdelsamad; Ayman Omar; Khurshid Ahmed Khan; Taher Al-Tweigeri; Ayman Elshentenawy; Adher Alsayed Journal: Breast Care (Basel) Date: 2020-04-06 Impact factor: 2.860
Authors: Hossein Taghizadeh; Robert M Mader; Leonhard Müllauer; Stefanie Aust; Stephan Polterauer; Heinz Kölbl; Veronika Seebacher; Christoph Grimm; Alexander Reinthaller; Gerald W Prager Journal: Oncologist Date: 2020-05-08
Authors: Tamara Díaz-Redondo; Rocio Lavado-Valenzuela; Begoña Jimenez; Tomas Pascual; Fernando Gálvez; Alejandro Falcón; Maria Del Carmen Alamo; Cristina Morales; Marta Amerigo; Javier Pascual; Alfonso Sanchez-Muñoz; Macarena González-Guerrero; Luis Vicioso; Aurora Laborda; Maria Victoria Ortega; Lidia Perez; Aranzazu Fernandez-Martinez; Nuria Chic; Jose Manuel Jerez; Martina Alvarez; Aleix Prat; Nuria Ribelles; Emilio Alba Journal: Front Oncol Date: 2019-11-05 Impact factor: 6.244